To achieve optimal virologic suppression for children undergoing antiretroviral therapy (ART), adherence must be excellent. This is defined as taking more than 95% of their prescribed doses. To our knowledge, no study in Ethiopia has evaluated the level of treatment adherence at the beginning of the child's treatment. Our aim was therefore to evaluate caregiver-reported ART non-adherence among children and any predictors for this during the early course of treatment. We conducted a prospective cohort study of 306 children with HIV in eight health facilities in Ethiopia who were registered at ART clinics between 20 December 2014 and 20 April 2015. The adherence rate reported by caregivers during the first week and after a month of treatment initiation was 92.8% and 93.8%, respectively. Our findings highlight important predictors of nonadherence. Children whose caregivers were not undergoing HIV treatment and care themselves were less likely to be non-adherent during the first week of treatment (aOR = 0.17, 95% CI: 0.04, 0.71) and the children whose caregivers did not use a medication reminder after one month of treatment initiation (aOR = 5.21, 95% CI: 2.23, 12.16) were more likely to miss the prescribed dose. Moreover, after one month of the treatment initiation, those receiving protease inhibitor (LPV/r) or ABC-based treatment regimens were more likely to be non-adherent (aOR = 12.32, 95% CI: 3.25, 46.67). To promote treatment adherence during ART initiation in children, particular emphasis needs to be placed on a baseline treatment regimen and ways to issue reminders about the child's medication to both the health care system and caregivers. Further, large scale studies using a combination of adherence measuring methods upon treatment initiation are needed to better define the magnitude and predictors of ART non-adherence in resource-limited settings.
Introduction
The introduction of antiretroviral therapy (ART) contributed to improved survival of children living with HIV (UNAIDS, 2016) . Its continued positive clinical impact depends on taking more than 95% of prescribed doses (Bhattacharya & Dubey, 2011; Jobanputra et al., 2015; MOH, 2007; WHO, 2013; Zoufaly et al., 2013) . Several factors affect the rate of treatment adherence among children including drug regimen, caregivers, and society and culture-related factors (Castro, Gonzalez, & Perez, 2015; Haberer & Mellins, 2009; Hagstromer, Lundstedt, Balcha, & Bjorkman, 2013; Muller et al., 2011; Reda & Biadgilign, 2012) . Of these factors, the level of commitment of caregivers highly determines the degree of treatment success among children (Castro et al., 2015; Haberer & Mellins, 2009; WHO, 2013) , as medication administration depends on a family caregiver (Muller et al., 2011) .
Previous studies on this topic focused on adults only and they employed either cross-sectional or retrospective designs. Studies from Ethiopia reported that ART treatment adherence in children ranged from 78.6% to 93.3% (Arage, Tessema, & Kassa, 2014; Biadgilign, Deribew, Amberbir, & Deribe, 2008; Biressaw, Abegaz, Abebe, Taye, & Belay, 2013) . A study conducted in sub-Saharan Africa indicated that ART adherence during the first six months of treatment predicted the prognostic value of virological and immunological responses and subsequent survival among adults (De Luca et al., 2012) . No study in Ethiopia has evaluated the level of treatment adherence in the beginning of a child's treatment. Our aim was therefore to evaluate caregiver-reported ART non-adherence and its predictors among children in the early stages of treatment.
Methods

Study design
This was a prospective cohort study conducted at eight health facilities in Oromia and Addis Ababa regions of Ethiopia.
Participants
Participants included family caregivers or responsible guardians aged 18 or above with a child aged between 3 months and 14 years newly registered for ART between 20 December 2014 and 20 April 2015. They were enrolled in the study within the first month of the child's ART treatment. Participants were coming to the facility every week in the first month and every month thereafter. The family caregivers were a parent, sibling, extended family member or legal guardian who had the main responsibility for regularly taking care of the child undergoing treatment. A child could have more than one caregiver in the family but only the primary caregiver was invited to participate. The minimum sample size was expected to be 300 including a 20% non-response rate.
At each clinic, data were collected by an ART provider assisted by a data clerk during the first week and at the end of the month of child's regular visit. They all received one-day training about data collection. Based on instruments used in similar studies, a study-specific questionnaire was adopted in addition to a protocol for documenting data from the child's medical records (Arage et al., 2014; Ebissa, Deyessa, & Biadgilign, 2015) . We used Self-Reported Adherence questionnaire as it was suggested to be a useful instrument for assessing ART adherence (Munoz-Moreno et al., 2007) . The questionnaire addressed socio-demographic, socioeconomic and disclosure variables of caregivers and children as well as the child's adherence to treatment. The protocol included clinical markers of the child including baseline CD4 count and WHO staging; and variables concerning the child's treatment regimen during treatment initiation. The instruments were piloted in two sites on 20 caregivers and their children and smaller modifications were made. Data were collected after 7 and then 30 days of initial treatment.
In this study, ART adherence rate was calculated as follows:
Doses prescribed − doses missed × 100 Doses prescribed .
Children were said to be non-adherent with ART if they took < 95% of the prescribed doses for 1 week and 30 days prior to the interview.
Data analysis
The IBM statistical package for social sciences version 22.0 was used for data entry and analysis (IBM Corporation, Armonk; NY, USA). Descriptive statistics were used to describe frequencies and proportion of caregiver and child characteristics. Levels of adherence dichotomized as non-adherent versus adherent at first week and first month and were the main outcome variables. Variables with p < .25 in the bivariate analysis were included in the multivariate analysis. We performed multivariate analysis using the binary logistic regression method and described measures of association as odds ratios with 95% CI. Statistical significance was set at p < .05.
Ethical consideration
The Written consent was obtained from all caregivers. Confidentiality was assured and explanation of the purpose and possible benefits and disadvantages of the study were provided.
Results
Socio-demographic characteristics
Of 306 caregivers and their children approached, three caregivers refused to participate making the response rate 99%. Most (82%) were females and 73% of the caregivers were biological parents or legal guardians of the children. Of the caregivers, 55% had disclosed their own HIV status to their family or others. Over a half (52%) of the children were boys. The median age of children at ART initiation was 9 (IQR = 6-12) years. Of those aged 6 years and above, 37% had been disclosed with their HIV diagnosis. Table 1 summarizes baseline characteristics.
Children whose caregivers were not undergoing HIV care and treatment themselves were less likely to be nonadherent (aOR = 0.17, 95% CI: 0.04, 0.71). After a month of treatment initiation, those receiving protease inhibitor (PI) (LPV/r) or abacavir (ABC)-based treatment regimen (aOR = 12.32, 95% CI: 3.25, 46.67) and the children whose caregivers did not use a medication reminder (aOR = 5.21, 95% CI: 2.23, 12.16) were more likely to be non-adherent (Table 2) .
Caregiver reported level of ART adherence
According to the caregivers' report, 93% and 94% of the children adhered to their prescribed ARV regimen in the first seven days and during the first month of treatment, respectively. In terms of missing doses, 19% of children missed at least one or more doses during the first month after treatment initiation.
The major reason reported by caregivers for missing an ARV dose during the first month of the child's treatment was forgetfulness, as reported by 46%, see Figure 1 .
Discussion
In this study, > 90% of children received ≥ 95% of prescribed doses after the first week and month of treatment initiation but missed doses were reported in about 19% of children. The most common reason for missing doses was care-givers' forgetfulness. The use of treatment reminders was associated with better adherence while the use of PI-based regimens predicted poorer adherence. The adherence rate in the current study is better than those reported from several low, middle and high income countries (Bhattacharya & Dubey, 2011; Kim, Gerver, Fidler, & Ward, 2014; Nyogea et al., 2015; Reda & Biadgilign, 2012; Ugwu & Eneh, 2013) . This could be because of the practice of providing intensive counselling and frequent follow-up by health care workers and adherence case managers, particularly in the first month of treatment (MOH, 2009) .
Higher rate of missed doses among those who did not use medication reminders highlights the well-recognized role of medication reminders for enhancing treatment adherence through behavioural change (WHO, 2013) . This is particularly relevant for a setting where forgetfulness is the most common reason for missing as reported both in the present and previous studies (Biadgilign et al., 2008; Biressaw et al., 2013) .
The rate of adherence was poorer among children receiving PI-based regimens. Poor palatability and adverse effects of PI-based regimens are known to contribute to poor adherence (Chandwani & Shuter, 2008; WHO, 2013 ), suggesting the need for more palatable treatment regimens.
The poorer adherence among those caregiver-child pairs enrolled in the same facility for treatment is contestable, as both need to be enrolled together if they are both HIV positive. Existing stigma and discrimination against people with HIV in the studied areas (Biru, Lundqvist, Molla, Jerene, & Hallstrom, 2015) could be a contributing factor for caregivers not to attend their nearby HIV clinic. This in turn may lead to missed appointments or failure to collect new medication (Reda & Biadgilign, 2012) . The other reason could be due to sub-optimal care being provided to the caregivers from the facility. This may result in a decreased level of commitment towards the child's treatment (WHO, 2013) .
The study has some limitations. Using the caregivers report method is likely to have overestimated the rate of adherence. Recall and social desirability biases are also a possibility. The use of prospective adherence measurement approach early in the course of the treatment is the main strength of this study.
Availing medication reminders, careful selection of ART regimens and improving child-caregiver communication with regard to disclosure of HIV status should be emphasized in HIV programmes. Further large scale study using a combination of adherence measuring methods in the beginning of treatment initiation is needed to bring forward a more convincing report in resource-limited settings.
